SOD1 Enzymatic Activity in CSF from ALS patients with and without SOD1 mutations

Leykam, L.; Forsberg, K. M.; Nordstrom, U.; Hjertqvist, K.; Oberg, A.; Jonsson, E.; Andersen, P. M.; Marklund, S. L.; Zetterstrom, P.

doi:10.1101/2024.06.15.599161

bioRxiv · 10.1101/2024.06.15.599161

SOD1 Enzymatic Activity in CSF from ALS patients with and without SOD1 mutations

Leykam, L.·Forsberg, K. M.·Nordstrom, U.·Hjertqvist, K.·Oberg, A.·Jonsson, E.·Andersen, P. M.·Marklund, S. L.·Zetterstrom, P.

View original source ↗Export metadata ↓

Abstract

Superoxide dismutase-1 (SOD1) mutations are a common cause of amyotrophic lateral sclerosis (ALS). Intrathecal gene therapy using the antisense-oligo-nucleotide drug tofersen to reduce SOD1 expression shows significant effects on disease progression and has recently been approved in the United States and the European Union. However, the discovery of children homozygous for four different inactivating SOD1 mutations developing the Infantile SOD1 Deficiency Syndrome (ISODDES) with injury to both upper and lower motor systems suggests that low SOD1 activities may be deleterious in humans. Monitoring SOD1 activity in cerebrospinal fluid (CSF) from tofersen-treated patients is advisable but difficult due to low levels and the presence of the isoenzyme SOD3. We here present a method to efficiently remove SOD3 from CSF using highly specific immobilized antibodies and subsequent measurement of the SOD activity as a sensitive assay for the SOD1 activity in CSF. We applied the method on CSF samples from ALS patients and controls and used paired erythrocyte samples for comparison. In ALS patients with wildtype SOD1, the SOD1 activity in CSF was the same as in controls, but patients with mutant SOD1 show lower activity in CSF, even patients with mutants previously reported to have full activity in erythrocytes. Activity variation is large among patients carrying the same SOD1 mutation and larger than seen in erythrocytes and in post-mortem central nervous system tissue. SOD1 in CSF shows a high specific activity, indicating that it is mainly native. Lastly, we identified a discrepancy between the SOD1 activity and protein level measured with ELISA in both CSF and erythrocytes. Since antibodies for SOD1 ELISA-quantification are raised against the native wildtype enzyme, the content of mutant SOD1s may be underestimated. Direct analysis of SOD1 enzymatic activity in CSF is therefore a more reliable way to monitor the effect of SOD1-lowering compounds.

Source connections

Published article ↗

Explore related subjects

neuroscience Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Leykam, L., Forsberg, K. M., Nordstrom, U., Hjertqvist, K., Oberg, A., Jonsson, E., Andersen, P. M., Marklund, S. L., Zetterstrom, P.. 2024-06-16. SOD1 Enzymatic Activity in CSF from ALS patients with and without SOD1 mutations. https://doi.org/10.1101/2024.06.15.599161

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience↗

bioRxiv2026

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience↗

bioRxiv2026

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience↗